C4 Therapeutics, Inc. (CCCC) files for IPO.

The IPO of C4 Therapeutics, Inc. will take place on October 1, 2020. C4 Therapeutics is a biopharmaceutical company that uses natural regulation of protein levels in the body to develop new therapeutic candidates for the destruction of disease causing proteins in the treatment of cancer, neurodegenerative conditions and other diseases. The company uses its own technological platform called TORPEDO (Target ORiented ProtEin Degrader Optimizer) to synthesize a new class of low molecular protein degradation products that are designed to selectively and effectively destroy disease-causing proteins.
 
The company’s expected value after the IPO will be $743 million.
 
Listed underwriters of the IPO are Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank.